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Summary
Cells lining the respiratory tract are equipped with mechanisms that dampen the effects of
oxidative stress. Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is a mediator involved in
regulating oxidative stress. Recent data indicate Nrf2 also controls expression of secretory
leukocyte protease inhibitor (SLPI). Sulforaphane (SFN), an isothiocyanate found in cruciferous
vegetables, enhances Nrf2 activity. Therefore, we hypothesized that SFN supplementation induces
SLPI secretion in the nasal mucosa in an Nrf2 dependent manner. Healthy nonsmoking adults
ingested SFN-containing broccoli shake homogenate (BSH) for 3 consecutive days. Nasal lavage
fluid (NLF) was collected before and after BSH ingestion and analyzed for SLPI protein levels. In
follow up in vitro experiments, differentiated primary nasal epithelial cells were used to evaluate
the relationship between SFN, Nrf2, and SLPI. Epithelial cells were transduced with Nrf2-specific
shRNA to examine the regulatory role of Nrf2 on SLPI expression. Supplementation with BSH
significantly increased SLPI levels in NLF. SFN supplementation in vitro significantly enhanced
SLPI secretion and these effects were significantly decreased in cells transduced with Nrf2-
specific shRNA.
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Our data support a relationship between nutritional supplementation, Nrf2 activation, and SLPI secretion. Therefore, ingestion of
SFN-containing foods has therapeutic potential to augment SLPI expression in the nasal mucosa.
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To combat and alleviate exogenous stressors, cells lining the respiratory tract have evolved
sophisticated sensing and signaling pathways to dampen the effects of cellular damage. The
transcription factor nuclear factor (erythroid-derived 2)-like 2 (Nrf2) plays a critical role in
maintaining respiratory homeostasis through the regulation of detoxifying enzymes and
antioxidants.1 Nrf2 has been shown to protect against infection and ameliorates the
development of respiratory disorders such as COPD and asthma.2,3
Recent data indicate that Nrf2 also regulates expression of an antiprotease, secretory
leukocyte protease inhibitor (SLPI), by binding to the antioxidant response element (ARE)
regions [GenBank AF205374] in the 1.2 kb promoter region of the SLPI gene.3,4 SLPI is an
11.7 kDa heavily disulfide bonded, positively charged protein found highly expressed in
epithelial cells at mucosal surfaces as well as in inflammatory cells such as neutrophils and
macrophages and contributes to host defense by regulating unchecked inflammation.5
Reduced levels of SLPI have been associated with several different respiratory diseases,
including emphysema, COPD, and cystic fibrosis.5
Agents known to increase Nrf2 activation and Nrf2-dependent gene expression include
sulforaphane (SFN), an isothiocyanate found in cruciferous vegetables. In the context of the
respiratory epithelium, SFN induces Nrf2 levels and exhibits protective effects in airway
epithelial cells via enhancing the expression of phase II enzymes.6 However, despite SFN
induction of Nrf2-dependent genes, its effect on the production and release of SLPI is not
known. As such, we hypothesize that ingestion of SFN-containing foods has therapeutic
potential to augment SLPI expression and secretion in an Nrf2 dependent manner. To test
this hypothesis, we conducted an in vivo nutritional supplementation study in a small cohort
of healthy volunteers as well as in vitro experiments to determine if SFN or SFN-containing
foods induce SLPI secretion in the nasal mucosa.
To test the impact of SFN-containing foods on SLPI secretion in vivo, we enrolled 12
healthy volunteers (Age: 24.8 ± 3.5; Sex: 6 Male, 6 Female; Race: 7 Caucasian, 4 African
American, 1 Asian; BMI: 25.8 ± 4.8) in a pilot clinical nutritional supplementation study
using a SFN-rich broccoshake homogenate (BSH). Commercially available Broccosprouts®
(Brassica Protection Products LLC) were used in the study and BSH were prepared similar
to a previously described formula and supplementation protocol, resulting in enhanced phase
II enzyme expression in the nasal mucosa.7 Briefly, 200 g Broccosprouts® were
homogenized with 4.8 oz water and frozen at −20 °C until the morning of the ingestion
protocol. Subjects were asked to consume the entire BSH and to keep a food diary. To
assure that the SFN content did not change over time in storage, we determined free SFN
levels in BSH as previously described and found that BSH samples prepared on two
different days, separated by three months, revealed similar free SFN levels, indicating batch
to batch compatibility (May SFN level: 95.9 µmol/L; Aug SFN level: 118 µmol/L).8
The BSH supplementation study took place over four consecutive days. Subjects were asked
to avoid ingestion of cruciferous vegetables for one week prior to and during the study.
Informed consent was obtained from all subjects and the protocol was approved by the UNC
Biomedical Institutional Review Board. Baseline nasal lavage fluid (NLF) was taken before
the first of three daily ingestions of BSH. Additional NLF samples were collected two hours
post ingestion of the second and third BSH dose as well as 24 h after the last ingestion. We
chose to collect NLF since it is a non-invasive, easily accessible procedure used in previous
BSH supplementation studies.7 All NLF samples were obtained and processed as previously
described.9 Cell-free NLF was analyzed for SLPI protein levels using commercially
available ELISA kits (R&D, Minneapolis, MN). Supplementation of human volunteers with
SFN-containing BSH enhanced SLPI levels in NLF within 24 h and was statistically
significant after 48 h BSH ingestion (Fig. 1A). Additionally we analyzed serum SLPI levels
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taken at baseline and 24 h post last BSH ingestion, to test if SLPI levels in the NLF were
from exudate or transudate. We found a slight non-statistically significant induction of SLPI
serum levels (data not shown). However, since serum was collected 24 h post last BSH
ingestion and considering the short half-life of SFN,7 we are not able to determine if SLPI
levels in the NLF are from exudate or transudate.
To confirm and expand these in vivo observations, we examined whether supplementation
of nasal epithelial cells (NEC) with SFN enhances production of SLPI. Human differentiated
EC were treated with 10 mM SFN from the basolateral side and analyzed for intracellular
and secreted SLPI levels 24 h post supplementation. Analysis of whole cell lysates using
Western blot indicated that SFN exposure did not enhance intracellular SLPI levels (data not
shown). However, secreted SLPI protein levels measured in the apical washes of
differentiated NEC were enhanced by SFN supplementation (Fig. 1B), corroborating the in
vivo data, which showed enhanced SLPI levels in the NLF.
To further investigate the link between SFN supplementation, Nrf2 activation, and nasal
SLPI expression, we used an in vitro model similar to previous studies.2 Based on these
previous studies, we determined that a SFN concentration of 10 µM is sufficient to
distinguish differences in Nrf2 dependent gene expression without causing cytotoxicity. 2
Specifically, to examine the effects of SFN supplementation on the transcriptional regulation
of SLPI, BEAS-2B cells, a human bronchial epithelial cell line, were transfected with a
SLPI promoter-reporter construct containing 1385 base pairs of the 5′ regulatory region of
the SLPI gene. Fig. 1C demonstrates that SFN supplementation significantly increased SLPI
gene transcriptional activation. To evaluate if SFN induction of SLPI gene expression was
dependent on Nrf2, we transduced BEAS-2B cells with lentiviral vectors that expressed
either Nrf2-specific shRNA (LV-Nrf2) or scrambled vectors expressing a nonspecific
sequence for use as a control (LV-Scr) as previously described.2 Transduced BEAS-2B cells
were subsequently transfected with the SLPI promoter-reporter and exposed to 10 µM SFN
for 5 h, demonstrating that reducing Nrf2 expression results in decreased SFN-induced SLPI
expression (Fig. 1C), thus mechanistically linking SFN, Nrf2, and SLPI expression.
Our study provides novel in vivo and in vitro evidence linking nutritional SFN
supplementation, Nrf2 activation, and enhanced SLPI secretion in the nasal mucosa. SLPI
inhibits proteases such as cathespin G and neutrophil elastase, which are both associated
with tissue damage in the context of chronic respiratory conditions like COPD and asthma.
In addition, we have recently demonstrated that SLPI protects against influenza A virus
(IAV) infection in nasal epithelial cells and that supplementation with SFN protects against
IAV entry.2,10 Since susceptibility to respiratory virus infection, including IAV, is enhanced
in subjects with COPD and asthma, our data suggest a potential role for nutritional
supplementation to improve respiratory defense and homeostasis in these subpopulations via
changes in the protease/antiprotease balance, which is an ongoing focus of our research.
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SFN supplementation induces SLPI secretion in vivo and in vitro and is mediated by Nrf2.
(A) Nasal lavage fluid obtained from 12 healthy volunteers on days 1–3 after daily BSH
ingestion was analyzed for SLPI protein levels. (B) Densitometric analysis of SLPI
expression in apical washes of NEC treated with SFN and normalized to levels in vehicle
treated cells from n = 5 different subjects. Representative Western blot of SLPI levels in
apical washes from NEC treated with vehicle (Veh) or SFN for 24 h (insert). (C) BEAS-2B
cells were transfected with SLPI-promoter reporter plasmid, exposed to 10 µM for 5 h, and
evaluated for SLPI gene transcription. SLPI-promoter reporter dependent luciferase activity
was normalized to Renilla levels and expressed as relative luciferase units (RLU). In some
experiments, BEAS-2B were transduced with lentiviral vectors encoding Nrf2-specific
shRNA (LV-Nrf2) or scrambled vectors (LV-Scr) 48 h prior to transfection with SLPI-
reporter plasmid and exposed to 10 µM for 5 h to evaluate SLPI-promoter reporter
dependent luciferase. *p < 0.05, **p < 0.01, ***p < 0.001.
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